-
02:15:08 PM

ENTA Stock News

09/17/23 12:00 PM
Nasdaq : ENTA
conferenceslow float
Enanta Pharmaceuticals to Present Data for EDP-323, its Oral, Once-Daily, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at the 9th ESWI Influenza Conference
Enanta Pharmaceuticals, Inc., a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections, today announced that data for EDP-323, its oral, once-daily, L-protein inhibitor in development for the treatment of respiratory syncytial virus, will be presented at the 9th European Scientific Working Group on...
RHEA-AI
neutral
09/07/23 7:00 AM
Nasdaq : ENTA
conferenceslow float
Enanta Pharmaceuticals to Present Data for EDP-938, its Oral, Once-Daily, N-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2023
Enanta Pharmaceuticals, Inc., a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections, today announced that data for EDP-938, its oral, once-daily, N-protein inhibitor in development for the treatment of respiratory syncytial virus, will be presented at IDWeek 2023 being held October 11- 15, 2023 at the...
RHEA-AI
neutral
08/07/23 4:01 PM
Nasdaq : ENTA
earningslow float
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter with Conference Call and Webcast Today at 4:30 p.m. ET
Enanta Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today reported financial results for its fiscal third quarter ended June 30, 2023.. Total revenue for the three months ended June 30, 2023 was $18.9 million and consisted of royalty revenue from worldwide net sales of...
RHEA-AI
neutral
07/31/23 7:00 AM
Nasdaq : ENTA
conferencesearningslow float
Enanta Pharmaceuticals to Host Conference Call on August 7 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal Third Quarter Ended June 30, 2023
Enanta Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that it plans to report its financial results for its fiscal third quarter ended June 30, 2023 after the U.S. market closes on August 7, 2023. Enanta management will host a conference call at 4:30 p.m. ET to...
RHEA-AI
neutral
06/20/23 7:00 AM
Nasdaq : ENTA
clinical triallow float
Enanta Pharmaceuticals Announces Positive Data From a Phase 1 Clinical Study of EDP-323, an Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus
Enanta Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections, today announced positive topline data from a Phase 1 study assessing the safety, tolerability, and pharmacokinetics of orally administered single ascending doses and multiple ascending doses of EDP-323 in healthy...
RHEA-AI
neutral
06/07/23 7:00 AM
Nasdaq : ENTA
low float
Enanta Pharmaceuticals Announces Data Presentation at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2023
Enanta Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that preclinical data from Enanta’ s out-licensing portfolio has been accepted for a poster presentation at the European Association for the Study of the Liver International Liver Congress 2023 being...
RHEA-AI
neutral
05/08/23 4:01 PM
Nasdaq : ENTA
clinical trialcovid-19low float
Enanta Pharmaceuticals Reports Positive Topline Results from Phase 2 SPRINT Trial Evaluating EDP-235 in Standard Risk Patients with COVID-19
Enanta Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced topline data from SPRINT, a double-blind, placebo-controlled Phase 2 clinical trial of EDP-235, Enanta’ s oral, 3 CL protease inhibitor, in non-hospitalized, symptomatic adults with mild or moderate COVID-19...
RHEA-AI
neutral